The global E3 ubiquitin protein ligase XIAP market is anticipated to grow at a significant CAGR during the forecast period. Ubiquitin ligase is also called as E3 ubiquitin ligase. It is a protein that staffs an E2 ubiquitin-conjugating enzyme that has been loaded with ubiquitin and recognizes a protein substrate while assisting or directly catalyzing the transfer of ubiquitin from the E2 to the protein substrate. The major factor for the growth of the market is the increasing prevalence of cancer across the globe.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/e3-ubiquitin-protein-ligase-xiap-market
According to the National Cancer Institute (NCI), it was estimated that 1,806,590 new cases of cancer will be diagnosed in the US with a mortality rate of 606,520 people in 2020. In men, prostate, lung, and colorectal cancers will account for an estimated 43% of all cancers diagnosed while for women, the three most common cancers are breast, lung, and colorectal which will account for an estimated 50% of all new cancer diagnoses in women in 2020. Furthermore, there were 18.1 million new cases and 9.5 million cancer-related mortalities globally in 2018 which is anticipated to rise to 29.5 million and the number of cancer-related mortalities to 16.4 million by 2040. Hence, the rising prevalence of cancer is driving the growth of the market as E3 ubiquitin protein ligase XIAP plays a crucial role in protein function and regulation.
Some major key players in the market include Novartis International AG, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. In addition, funding opportunity has been witnessed, which in turn, is expected to drive the market growth during the forecast period. For instance, in June 2021, Stablix Therapeutics announced a $63 million Series A financing which was led by founding investor Versant Ventures with NEA, Cormorant, Euclidean Capital and Alexandria Real Estate Equities. Stablix is a biotechnology company that pioneers in the field of Targeted Protein Stabilization (TPS).
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Type
o By Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Novartis International AG, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Ltd., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global E3 Ubiquitin Protein Ligase XIAP Market Report by Segment
By Type
- ASTX-660
- FL-118
- AD-O53.2
- LCL-161
- SM-1200
- Others
By Application
- Solid Tumor
- Fallopian Tube Cancer
- Lung Cancer
- Peritoneal Cancer
- Others
A full report of E3 Ubiquitin Protein Ligase XIAP Market is available at: https://www.omrglobal.com/industry-reports/e3-ubiquitin-protein-ligase-xiap-market
E3 Ubiquitin Protein Ligase XIAP Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Novartis International AG
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Company Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
